Sujal Shah

2021

In 2021, Sujal Shah earned a total compensation of $2.2M as Chief Executive Officer at Cymabay Therapeutics, a 16% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$320,100
Option Awards$1,338,482
Salary$550,000
Other$3,773
Total$2,212,355

Shah received $1.3M in option awards, accounting for 61% of the total pay in 2021.

Shah also received $320.1K in non-equity incentive plan, $550K in salary and $3.8K in other compensation.

Rankings

In 2021, Sujal Shah's compensation ranked 5,663rd out of 12,415 executives tracked by ExecPay. In other words, Shah earned more than 54.4% of executives.

ClassificationRankingPercentile
All
5,663
out of 12,415
54th
Division
Manufacturing
2,400
out of 5,505
56th
Major group
Chemicals And Allied Products
1,045
out of 2,375
56th
Industry group
Drugs
933
out of 2,096
56th
Industry
Pharmaceutical Preparations
672
out of 1,546
57th
Source: SEC filing on April 26, 2022.

Shah's colleagues

We found four more compensation records of executives who worked with Sujal Shah at Cymabay Therapeutics in 2021.

2021

Dennis Kim

Cymabay Therapeutics

Chief Medical Officer

2021

Lewis Stuart

Cymabay Therapeutics

Chief Commercial Officer

2021

Charles McWherter

Cymabay Therapeutics

President of R&D

2021

Paul Quinlan

Cymabay Therapeutics

General Counsel

News

In-depth

You may also like